– USA, MA – Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and immunological diseases, announced the appointment of Dr. Anil Singhal (Ph.D.) to its board of directors.
“I am pleased to welcome Dr. Singhal to our board of directors at this exciting time for our company,” said co-founder and Board chairman, Dr. Luke Evnin. “With over 30 years of oncology research and development leadership and execution, Dr. Singhal’s proven experience represents a critical addition to our board’s skill set.”
Concurrently, Derek DiRocco will resign from the Board effective as of the 2025 AGM.
About Dr. Anil Singhal
Dr. Anil Singhal joins the board of Werewolf Therapeutics with over three decades of research and development experience in the biopharmaceutical industry. He is the President and CEO of Trishula Therapeutics, Inc., a private biotechnology company. Before that, Dr. Singhal served as the President and CEO and a member of the board of directors of Adicet Bio, Inc., where he led the then-private biotechnology company to its first oncology investigational new drug application submission and its merger with resTOR bio, Inc.
“I am thrilled to join Werewolf’s board of directors as the company advances its novel INDUKINE molecules through clinical development,” said Dr. Anil Singhal. “Werewolf is demonstrating the power of the PREDATORTM protein engineering platform and its potential to provide safer and more efficacious treatments for cancer and immunological diseases.”
Dr. Anil Singhal is a member of the American Association of Cancer Research and a member of the American Society of Clinical Oncology. He received his B.Sc Honours degree in Biochemistry from Panjab University in India, his MBA in Business Administration from the University of Washington, and his Ph.D. in Biochemistry from Rutgers University.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent.
For more: https://werewolftx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.